Homocysteine-lowering vitamins and cardiovascular mortality: are they really effective?
In the light of current data obtained from prospective outcome studies, we believe that it is premature to support the use of homocysteine-lowering vitamins including folic acid in patients with established coronary artery disease in order to improve cardiovascular outcomes. We think that future large-scale epidemiological trials with very long-term follow-up periods will probably solve this dilemma.